Personalized medicine has taken somewhat of a back burner in the wake of reform, but the science continues to evolve. An interesting report looks at how the Department of Defense might be able to use genetic information, particularly as it becomes much less expensive to acquire.
Personalized medicine sometimes gets lost in the debate over other major health care issues, but it is probably the single most significant development in the actual delivery of medical care and will be so for the next decade. A new report details reimbursement hurdles to growth of the field.
The days shorten but the potpourri stays strong, this week including information on the safety of FDA-cleared devices; medication adherence; genetic tests; the FDA and CMS working together to review products; state all-payer databases and the increasing control of physician practices by hospital systems.
Summer nears an end, but not our Potpourris. This one includes the costs of malpractice, an innovative provider error disclosure program, employer wellness paybacks, blood pressure medication issues, the cost of new technologies, provider pricing power and the mental health of Californians.
Personalized medicine relies on genetic testing for much of its information. Direct-to-consumer genetic testing firms are widespread and a GAO report reveals that much of their work appears shoddy and their marketing deceptive. More regulation appears needed and on the way.
A critical component of personalized medicine is various molecular diagnostic tests. AHRQ has issued a lengthy report on the state of these tests, examining their quality and clinical utility.
Another weekend bonanza of health care items, including health insurance premium increases, genetic testing, remote patient monitoring, eye drug coverage by Medicare, emergency room use under the reform law and paying people to take their medicine.
More health care nuggets for the weekend, including personalized medicine, health reform, health insurance premiums, telemedicine, and community health centers.
Direct-to-consumer genetic tests are becoming more prevalent. Pathway Genetics strikes a distribution deal with Walgreens, but draws FDA scrutiny over whether needed regulatory filings have been performed.